Examining the details of a recent study by FDA elucidates the fact that the prime reason for the 40 percent failure rate of drugs which even pass through the Phase III clinical trials is lack of proper understanding of biology. Outperforming a bulk of organizations tasting undesired clinical trial results, Innovate Research engraves its uniqueness as an end-to-end service provider for disparate clinical studies (covering all therapeutic areas) fortified by its clinical, regulatory and site experts with exemplary technical knowledge.

As a small error can sprout up tangential results, Innovate’s adroit team ensures to ask critical questions pertaining to the client’s goals, discuss the right pathways & strategies by incorporating other industry experts’ advices, align the development process with global stakeholders and only then devise top-notch solutions. “We assimilate the subtleties in our clients’ requirements, transform their promising ideas into commercial reality and compute tailor-made costs for the devised solutions by being their trustworthy partner,”explains Devesh Kumar& Sushant Tyagi, Founders& Directors, Innovate Research.

Step-wise Assistance
Once the client’s requirements are garnered, Innovate’s team recruits the requisite study participants, assigns a dedicated project team (project management, regulatory, quality & scientific specialists) and deploys the study in a modern clinical facility. Later on through PoC, they perform Phase I clinical trials across multiple locations at once in order to obtain accurate and useful data which indeed fuel the next stage in the process. Post the execution of Phase I trials, Innovate’s well-experienced clinical teams handle the most complex Phase II & Phase III trials(regulatory submission) with utmost diligence to reduce delays, errors and costs, and also to enrich efficiencies, process speeds and data accuracy.

Innovate attributes its seamless development of new chemical entities, creation of innovative therapies and research on novel drug delivery systems to its partnership with both national and international companies that are engrossed in clinical studies

Besides monitoring the long-term effects of client’s new drug and managing its related safety data, the firm’s late phase expertise aids them in implementing a market strategy to elevate their brand value and establish an unbeatable market position. In a nutshell, its fleet of integrated services not just encompasses aforementioned clinical trial management services but site & investigator management, clinical data

management, biostatistics, medical affairs & personal healthcare, and third party auditing / monitoring & consulting services too.

Innovate attributes its seamless development of new chemical entities, creation of innovative therapies and research on novel drug delivery systems to its partnership with both national and international companies that are engrossed in clinical studies. It offers paperless clinical trials management solutions via technologies like eCRF, IWRS, eTMFs, CTMS and ePD, which helps deliver timely and cost-effective solutions to domestic clients. The company also strictly adhere to regulatory guidelines like ICMR, Schedule Y, ICH-GCP, Indian GCP and 21 CFR 11.

Holistic Edification
As continuous learning is highly essential for efficacious outcomes from any work process, Innovate has framed a holistic and integrated employee learning approach and a dedicated employee development approach to bolster the ethicality, efficiency, data quality and safety of each new medical therapy. Moreover, its 26 employees attend weekly training sessions and conferences to get updated on the latest advancements in the industry.

Currently spread across Delhi, Mumbai and Lucknow, Innovate has been renowned as the fastest growing CRO by Red Herring in 2014 and as the best clinical research service provider by Worldwide Achievers in 2017. To match the current standards, it constantly updates all its electronic databases; no wonder it has witnessed a significant increase in revenue from $1000 in 2014 (inception) to $350000 in 2017.